lactic acid has been researched along with Osteomyelitis in 37 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Osteomyelitis: INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to investigate the curative effect of bone-like hydroxyapatite/poly amino acid (BHA/PAA) as a carrier for poly(lactic-co-glycolic acid)-coated rifapentine microsphere (RPM) in the treatment of rabbit chronic osteomyelitis induced by Staphylococcus aureus." | 7.81 | Treatment of Staphylococcus aureus-induced chronic osteomyelitis with bone-like hydroxyapatite/poly amino acid loaded with rifapentine microspheres. ( Cao, ZD; Jiang, DM; Li, YJ; Wang, X; Wang, ZL; Wu, J; Yan, L; Yi, YF, 2015) |
| " Here we propose polymeric nanoparticles as locally applied gentamicin delivery system useful in osteomyelitis therapy." | 7.81 | Gentamicin loaded PLGA nanoparticles as local drug delivery system for the osteomyelitis treatment. ( Brzychczy-Włoch, M; Pamuła, E; Posadowska, U, 2015) |
| "Fluconazole poly(D,L-lactic) acid (PLA) and poly(L-lactic) acid (L-PLA) implantable delivery rods were studied, in vitro and in vivo, as an alternative treatment of fungal osteomyelitis." | 7.73 | Biodegradable implantable fluconazole delivery rods designed for the treatment of fungal osteomyelitis: influence of gamma sterilization. ( Evora, C; Martín, AY; Sánchez, E; Soriano, I, 2006) |
| "A novel biodegradable system of D-,L-dilactide delivering pefloxacin was implanted in 104 rabbits with experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus (MRSA), 26 serving as controls." | 7.70 | Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin. ( Andreopoulos, A; Dounis, E; Galanakis, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Karagianakos, P; Papakostas, K; Rifiotis, C, 2000) |
| "Gentamicin was assayed spectrophotometrically at 332 nm after derivation with the o-phthalaldehyde; biodegradable polymers studied did not interfere with this method of gentamicin analysis." | 5.34 | Improvement of gentamicin poly(D,L-lactic-co-glycolic acid) microspheres for treatment of osteomyelitis induced by orthopedic procedures. ( Elorza, B; Elorza, Mde L; Frutos, G; Torrado, S; Virto, MR, 2007) |
| "This study aimed to develop a drug delivery system with hybrid biodegradable antifungal and antibacterial agents incorporated into poly lactic-co-glycolic acid (PLGA) nanofibers, facilitating an extended release of fluconazole, vancomycin, and ceftazidime to treat polymicrobial osteomyelitis." | 4.31 | Sustained Release of Antifungal and Antibacterial Agents from Novel Hybrid Degradable Nanofibers for the Treatment of Polymicrobial Osteomyelitis. ( Chou, YC; Hsu, YH; Lin, YT; Liu, SJ; Lu, CJ; Ueng, SW; Yu, YH, 2023) |
| "The purpose of this study was to investigate the curative effect of bone-like hydroxyapatite/poly amino acid (BHA/PAA) as a carrier for poly(lactic-co-glycolic acid)-coated rifapentine microsphere (RPM) in the treatment of rabbit chronic osteomyelitis induced by Staphylococcus aureus." | 3.81 | Treatment of Staphylococcus aureus-induced chronic osteomyelitis with bone-like hydroxyapatite/poly amino acid loaded with rifapentine microspheres. ( Cao, ZD; Jiang, DM; Li, YJ; Wang, X; Wang, ZL; Wu, J; Yan, L; Yi, YF, 2015) |
| " Here we propose polymeric nanoparticles as locally applied gentamicin delivery system useful in osteomyelitis therapy." | 3.81 | Gentamicin loaded PLGA nanoparticles as local drug delivery system for the osteomyelitis treatment. ( Brzychczy-Włoch, M; Pamuła, E; Posadowska, U, 2015) |
| "Fluconazole poly(D,L-lactic) acid (PLA) and poly(L-lactic) acid (L-PLA) implantable delivery rods were studied, in vitro and in vivo, as an alternative treatment of fungal osteomyelitis." | 3.73 | Biodegradable implantable fluconazole delivery rods designed for the treatment of fungal osteomyelitis: influence of gamma sterilization. ( Evora, C; Martín, AY; Sánchez, E; Soriano, I, 2006) |
| " The purpose of this investigation was to develop and characterize a biodegradable, implantable delivery system containing ciprofloxacin hydrochloride (HCl) for the localized treatment of osteomyelitis and to study the extent of drug penetration from the site of implantation into the bone." | 3.70 | In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. ( Ramchandani, M; Robinson, D, 1998) |
| "A novel biodegradable system of D-,L-dilactide delivering pefloxacin was implanted in 104 rabbits with experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus (MRSA), 26 serving as controls." | 3.70 | Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin. ( Andreopoulos, A; Dounis, E; Galanakis, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Karagianakos, P; Papakostas, K; Rifiotis, C, 2000) |
| "Antibiotic treatment of osteomyelitis with the current degradable and non-degradable delivery devices is effective in the majority of cases." | 2.49 | Biodegradable vs non-biodegradable antibiotic delivery devices in the treatment of osteomyelitis. ( Busscher, HJ; Kluin, OS; Neut, D; van der Mei, HC, 2013) |
| "In the conventional treatment of osteomyelitis, the penetration of antibiotics into the infected bone is commonly poor." | 1.40 | Inflammation-induced drug release by using a pH-responsive gas-generating hollow-microsphere system for the treatment of osteomyelitis. ( Chia, WT; Chung, MF; Hsiao, CW; Hsiao, HC; Liu, HY; Sung, HW; Yang, CM, 2014) |
| " Hence, these microspheres may be potentially useful in the clinical setting with the need for further investigation for optimal dosing of TCP–PLGA microspheres." | 1.36 | Biodegradable microspherical implants containing teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. ( Ahiskali, R; Cevher, E; Mülazimoğlu, L; Orhan, Z; Sensoy, D; Yildiz, A, 2010) |
| "Gentamicin was assayed spectrophotometrically at 332 nm after derivation with the o-phthalaldehyde; biodegradable polymers studied did not interfere with this method of gentamicin analysis." | 1.34 | Improvement of gentamicin poly(D,L-lactic-co-glycolic acid) microspheres for treatment of osteomyelitis induced by orthopedic procedures. ( Elorza, B; Elorza, Mde L; Frutos, G; Torrado, S; Virto, MR, 2007) |
| "Gentamicin-loaded discs were produced by compressing microparticle-gentamicin mixture obtained by spray drying a mixture of gentamicin in a solution of a biodegradable polymer." | 1.33 | In vitro and in vivo release of gentamicin from biodegradable discs. ( Fu, YC; Guan Lee, HC; Lee, DJ; Naraharisetti, PK; Wang, CH, 2006) |
| "Osteomyelitis was established in 40 New Zealand White rabbits using Staphylococcus aureus." | 1.32 | Effective treatment of osteomyelitis with biodegradable microspheres in a rabbit model. ( Ambrose, CG; Clyburn, TA; Gogola, GR; Gulati, P; Joseph, J; Louden, K; Mikos, AG; Wright, J, 2004) |
| "Osteomyelitis is generally treated by the systemic administration of antibiotics and continuous irrigation after curettage of the lesion, and bone graft is performed secondarily to treat any bone defect." | 1.30 | Apatite cement containing antibiotics: efficacy in treating experimental osteomyelitis. ( Ishii, Y; Sasaki, S, 1999) |
| "Chronic osteomyelitis is one of the most serious complications of orthopedic open fracture treatment." | 1.29 | Controlled release of antibiotics from coated orthopedic implants. ( Arm, DM; Bohach, GA; Price, JS; Tencer, AF, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (18.92) | 18.2507 |
| 2000's | 14 (37.84) | 29.6817 |
| 2010's | 15 (40.54) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, YH | 1 |
| Yu, YH | 1 |
| Chou, YC | 1 |
| Lu, CJ | 1 |
| Lin, YT | 1 |
| Ueng, SW | 2 |
| Liu, SJ | 2 |
| Makiishi, J | 1 |
| Matsuno, T | 2 |
| Ito, A | 2 |
| Sogo, Y | 2 |
| Satoh, T | 2 |
| Uskoković, V | 1 |
| Hoover, C | 1 |
| Vukomanović, M | 1 |
| Uskoković, DP | 1 |
| Desai, TA | 1 |
| Chung, MF | 1 |
| Chia, WT | 1 |
| Liu, HY | 1 |
| Hsiao, CW | 1 |
| Hsiao, HC | 1 |
| Yang, CM | 1 |
| Sung, HW | 1 |
| McLaren, JS | 1 |
| White, LJ | 1 |
| Cox, HC | 1 |
| Ashraf, W | 1 |
| Rahman, CV | 1 |
| Blunn, GW | 1 |
| Goodship, AE | 1 |
| Quirk, RA | 1 |
| Shakesheff, KM | 1 |
| Bayston, R | 1 |
| Scammell, BE | 1 |
| Kankilic, B | 1 |
| Bilgic, E | 1 |
| Korkusuz, P | 1 |
| Korkusuz, F | 1 |
| Yan, L | 1 |
| Jiang, DM | 1 |
| Cao, ZD | 1 |
| Wu, J | 1 |
| Wang, X | 1 |
| Wang, ZL | 1 |
| Li, YJ | 1 |
| Yi, YF | 1 |
| Posadowska, U | 3 |
| Brzychczy-Wloch, M | 1 |
| Pamula, E | 1 |
| Brzychczy-Włoch, M | 2 |
| Pamuła, E | 2 |
| Drożdż, A | 1 |
| Krok-Borkowicz, M | 1 |
| Włodarczyk-Biegun, M | 1 |
| Dobrzyński, P | 1 |
| Chrzanowski, W | 1 |
| Yang, H | 1 |
| Hao, Y | 1 |
| Liu, Q | 1 |
| Mi, Z | 1 |
| Wang, Z | 1 |
| Zhu, L | 1 |
| Feng, Q | 1 |
| Hu, N | 1 |
| Pillai, RR | 1 |
| Somayaji, SN | 1 |
| Rabinovich, M | 1 |
| Hudson, MC | 1 |
| Gonsalves, KE | 1 |
| Orhan, Z | 2 |
| Cevher, E | 2 |
| Yildiz, A | 1 |
| Ahiskali, R | 2 |
| Sensoy, D | 2 |
| Mülazimoğlu, L | 2 |
| Yuan, LJ | 1 |
| Lin, SS | 1 |
| Chan, EC | 1 |
| Chen, KT | 1 |
| Lee, MS | 1 |
| Tamazawa, G | 1 |
| Miyai, T | 1 |
| Kitahara, K | 1 |
| Kimishima, K | 1 |
| Emanuel, N | 1 |
| Rosenfeld, Y | 1 |
| Cohen, O | 1 |
| Applbaum, YH | 1 |
| Segal, D | 1 |
| Barenholz, Y | 1 |
| Kluin, OS | 1 |
| van der Mei, HC | 1 |
| Busscher, HJ | 1 |
| Neut, D | 1 |
| Borisov, IV | 1 |
| Amiraslanov, IuA | 1 |
| Blatun, LA | 1 |
| Ambrose, CG | 1 |
| Clyburn, TA | 1 |
| Louden, K | 1 |
| Joseph, J | 1 |
| Wright, J | 1 |
| Gulati, P | 1 |
| Gogola, GR | 1 |
| Mikos, AG | 1 |
| Bongaerts, GP | 1 |
| Schreurs, BW | 1 |
| Lunel, FV | 1 |
| Lemmens, JA | 1 |
| Pruszczynski, M | 1 |
| Merkx, MA | 1 |
| Koort, JK | 2 |
| Mäkinen, TJ | 2 |
| Suokas, E | 2 |
| Veiranto, M | 2 |
| Jalava, J | 2 |
| Knuuti, J | 1 |
| Törmälä, P | 2 |
| Aro, HT | 2 |
| Garvin, K | 1 |
| Feschuk, C | 1 |
| Naraharisetti, PK | 1 |
| Guan Lee, HC | 1 |
| Fu, YC | 1 |
| Lee, DJ | 1 |
| Wang, CH | 1 |
| Soriano, I | 1 |
| Martín, AY | 1 |
| Evora, C | 1 |
| Sánchez, E | 1 |
| Kent, ME | 1 |
| Rapp, RP | 1 |
| Smith, KM | 1 |
| Sayin, B | 1 |
| Caliş, S | 1 |
| Atilla, B | 1 |
| Marangoz, S | 1 |
| Hincal, AA | 1 |
| Virto, MR | 1 |
| Elorza, B | 1 |
| Torrado, S | 1 |
| Elorza, Mde L | 1 |
| Frutos, G | 1 |
| Kan, PL | 1 |
| Sağirli, O | 1 |
| Zhang, X | 1 |
| Wyss, UP | 1 |
| Pichora, D | 1 |
| Goosen, MF | 1 |
| Price, JS | 1 |
| Tencer, AF | 1 |
| Arm, DM | 1 |
| Bohach, GA | 1 |
| Calhoun, JH | 1 |
| Mader, JT | 1 |
| Benoit, MA | 1 |
| Mousset, B | 1 |
| Delloye, C | 1 |
| Bouillet, R | 1 |
| Gillard, J | 1 |
| Ramchandani, M | 1 |
| Robinson, D | 1 |
| Sasaki, S | 1 |
| Ishii, Y | 1 |
| Kanellakopoulou, K | 1 |
| Galanakis, N | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Rifiotis, C | 1 |
| Papakostas, K | 1 |
| Andreopoulos, A | 1 |
| Dounis, E | 1 |
| Karagianakos, P | 1 |
| Giamarellou, H | 1 |
| Wei, G | 1 |
| Kotoura, Y | 1 |
| Oka, M | 1 |
| Yamamuro, T | 1 |
| Wada, R | 1 |
| Hyon, SH | 1 |
| Ikada, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A National, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute in Filling of Contained Bone Defects[NCT00841152] | 120 participants (Actual) | Observational | 2009-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for lactic acid and Osteomyelitis
| Article | Year |
|---|---|
Biodegradable vs non-biodegradable antibiotic delivery devices in the treatment of osteomyelitis.
Topics: Absorbable Implants; Animals; Anti-Bacterial Agents; Dioxanes; Drug Delivery Systems; Humans; Lactic | 2013 |
[Antibacterial therapy for osteomyelitis (a systematized review)].
Topics: Administration, Oral; Anti-Bacterial Agents; Drug Carriers; Gram-Negative Bacteria; Humans; Lactic A | 2003 |
Polylactide-polyglycolide antibiotic implants.
Topics: Absorbable Implants; Animals; Anti-Bacterial Agents; Biocompatible Materials; Coated Materials, Bioc | 2005 |
Antibiotic beads and osteomyelitis: here today, what's coming tomorrow?
Topics: Absorbable Implants; Animals; Anti-Bacterial Agents; Calcium Sulfate; Drug Compounding; Drug Deliver | 2006 |
33 other studies available for lactic acid and Osteomyelitis
| Article | Year |
|---|---|
Sustained Release of Antifungal and Antibacterial Agents from Novel Hybrid Degradable Nanofibers for the Treatment of Polymicrobial Osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Ceftazidime; Delayed-Action Preparations; Flucona | 2023 |
In vitro/in vivo evaluation of the efficacy of gatifloxacine-loaded PLGA and hydroxyapatite composite for treating osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Bacteroides fragilis; Biocompatible Materials; Bone Regeneration; De | 2017 |
Osteogenic and antimicrobial nanoparticulate calcium phosphate and poly-(D,L-lactide-co-glycolide) powders for the treatment of osteomyelitis.
Topics: Animals; Anti-Infective Agents; Calcium Phosphates; Cell Line; Clindamycin; Collagen Type I; Core Bi | 2013 |
Inflammation-induced drug release by using a pH-responsive gas-generating hollow-microsphere system for the treatment of osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Bone Cements; Calcium Phosphates; Carbon Dioxide; Delayed-Action Pre | 2014 |
A biodegradable antibiotic-impregnated scaffold to prevent osteomyelitis in a contaminated in vivo bone defect model.
Topics: Animals; Anti-Infective Agents; Biodegradable Plastics; Bone Regeneration; Clindamycin; Femur; Genta | 2014 |
Vancomycin containing PLLA/β-TCP controls experimental osteomyelitis in vivo.
Topics: Animals; Bone Development; Bone-Implant Interface; Calcium Phosphates; Lactic Acid; Male; Methicilli | 2014 |
Treatment of Staphylococcus aureus-induced chronic osteomyelitis with bone-like hydroxyapatite/poly amino acid loaded with rifapentine microspheres.
Topics: Amino Acids; Animals; Anti-Bacterial Agents; Chronic Disease; Delayed-Action Preparations; Drug Carr | 2015 |
Injectable gellan gum-based nanoparticles-loaded system for the local delivery of vancomycin in osteomyelitis treatment.
Topics: Anti-Bacterial Agents; Cell Line; Cell Survival; Humans; Lactic Acid; Microbial Sensitivity Tests; N | 2016 |
Gentamicin loaded PLGA nanoparticles as local drug delivery system for the osteomyelitis treatment.
Topics: Drug Delivery Systems; Drug Liberation; Gentamicins; Lactic Acid; Microbial Sensitivity Tests; Micro | 2015 |
Injectable hybrid delivery system composed of gellan gum, nanoparticles and gentamicin for the localized treatment of bone infections.
Topics: Anti-Bacterial Agents; Biocompatible Materials; Drug Carriers; Gentamicins; Humans; Injections, Intr | 2016 |
Preparation and in vitro study of hydrochloric norvancomycin encapsulated poly (d,l-lactide-co-glycolide, PLGA) microspheres for potential use in osteomyelitis.
Topics: Capsules; Drug Carriers; Drug Liberation; Lactic Acid; Microspheres; Oils; Osteomyelitis; Particle S | 2017 |
Nafcillin-loaded PLGA nanoparticles for treatment of osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Cells, Cultured; Drug Carriers; Humans; Lactic Acid; Mice; Nafcillin | 2008 |
Biodegradable microspherical implants containing teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
Topics: Absorbable Implants; Analysis of Variance; Animals; Anti-Bacterial Agents; Disease Models, Animal; D | 2010 |
In vitro and in vivo analysis of a biodegradable poly(lactide-co-glycolide) copolymer capsule and collagen composite system for antibiotics and bone cells delivery.
Topics: Alkaline Phosphatase; Animals; Biocompatible Materials; Bone and Bones; Calcium; Capsules; Cells, Cu | 2011 |
Gatifloxacine-loaded PLGA and β-tricalcium phosphate composite for treating osteomyelitis.
Topics: Absorbable Implants; Animals; Anti-Infective Agents; Bacteriological Techniques; Bacteroides fragili | 2011 |
A lipid-and-polymer-based novel local drug delivery system--BonyPid™: from physicochemical aspects to therapy of bacterially infected bones.
Topics: Animals; Anti-Bacterial Agents; Calcium Phosphates; Chemical Phenomena; Coated Materials, Biocompati | 2012 |
Effective treatment of osteomyelitis with biodegradable microspheres in a rabbit model.
Topics: Animals; Anti-Bacterial Agents; Biocompatible Materials; Cefazolin; Disease Models, Animal; Drug Car | 2004 |
Was isolation of Veillonella from spinal osteomyelitis possible due to poor tissue perfusion?
Topics: Aged; Humans; Lactic Acid; Male; Osteomyelitis; Thoracic Vertebrae; Veillonella | 2004 |
Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Bone Cements; Ciprofloxacin; Coated Materials, Biocompatible; Diseas | 2005 |
In vitro and in vivo release of gentamicin from biodegradable discs.
Topics: Animals; Biodegradation, Environmental; Delayed-Action Preparations; Femur; Gentamicins; Kinetics; L | 2006 |
Biodegradable implantable fluconazole delivery rods designed for the treatment of fungal osteomyelitis: influence of gamma sterilization.
Topics: Animals; Antifungal Agents; Biocompatible Materials; Drug Delivery Systems; Fluconazole; Gamma Rays; | 2006 |
Implantation of vancomycin microspheres in blend with human/rabbit bone grafts to infected bone defects.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biocompatible Materials; Bone Transplantatio | 2006 |
Improvement of gentamicin poly(D,L-lactic-co-glycolic acid) microspheres for treatment of osteomyelitis induced by orthopedic procedures.
Topics: Antineoplastic Agents; Biocompatible Materials; Catalysis; Drug Delivery Systems; Gentamicins; Human | 2007 |
Sodium fusidate-poly(D,L-lactide-co-glycolide) microspheres: preparation, characterisation and in vivo evaluation of their effectiveness in the treatment of chronic osteomyelitis.
Topics: Animals; Calorimetry, Differential Scanning; Chronic Disease; Drug Carriers; Fusidic Acid; Lactic Ac | 2007 |
Sustained release of ciprofloxacin from an osteoconductive poly(DL)-lactide implant.
Topics: Absorbable Implants; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Delayed-A | 2008 |
Biodegradable controlled antibiotic release devices for osteomyelitis: optimization of release properties.
Topics: Biocompatible Materials; Biodegradation, Environmental; Cefazolin; Delayed-Action Preparations; Gent | 1994 |
Controlled release of antibiotics from coated orthopedic implants.
Topics: Anti-Bacterial Agents; Biocompatible Materials; Gentamicins; Kinetics; Lactic Acid; Microbial Sensit | 1996 |
Treatment of osteomyelitis with a biodegradable antibiotic implant.
Topics: Animals; Anti-Bacterial Agents; Biodegradation, Environmental; Disease Models, Animal; Drug Delivery | 1997 |
Antibiotic-loaded plaster of Paris implants coated with poly lactide-co-glycolide as a controlled release delivery system for the treatment of bone infections.
Topics: Animals; Anti-Bacterial Agents; Biocompatible Materials; Biodegradation, Environmental; Calcium Sulf | 1997 |
In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants.
Topics: Animals; Anti-Infective Agents; Biocompatible Materials; Capsules; Ciprofloxacin; Disease Models, An | 1998 |
Apatite cement containing antibiotics: efficacy in treating experimental osteomyelitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Apatites; Bone Cements; Bone Marrow; Bone T | 1999 |
Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin.
Topics: Animals; Anti-Infective Agents; Colony Count, Microbial; Drug Implants; Excipients; Lactic Acid; Mal | 2000 |
A bioabsorbable delivery system for antibiotic treatment of osteomyelitis. The use of lactic acid oligomer as a carrier.
Topics: Absorption; Animals; Biocompatible Materials; Blood Urea Nitrogen; Bone and Bones; Bone Marrow; Crea | 1991 |